2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 43

Novel Anti-Malarial Drug Derivative Inhibited Anti-Citrullinated Protein/Peptide Antibodies and Rheumatoid Factors Production in Dnaseii/Ifnr Double Knock out Mice
Abstract Number: 44

Histone Deacetylase 1 (HDAC1): A Novel Therapeutic Target in Patients with Rheumatoid Arthritis
Abstract Number: 45

CKD-506, First-in-Class Histone Deacetylase (HDAC) 6 Inhibitor, Ameliorates Rheumatoid Arthritis through Regulation of Inflammation and T Cell Function
Abstract Number: 46

Organic Dust Inhalants Shift Immune Responses and Extracellular Matrix Balance between Synovium and Lung in the Collagen-Induced Arthritis Mouse Model
Abstract Number: 47

Analysis of the Role of RORγt+Foxp3+ T Regulatory 17 (Tr17) Cells in Murine Autoimmune Arthritis Model
Abstract Number: 48

In Vivo Demonstration of Tmtnf Reverse Signaling: Significance in the Therapeutic Response to Anti-TNF Agents during Murine Arthritis
Abstract Number: 49

Tofacitinib Facilitates the Expansion of Myeloid-Dirived Suppressor Cells and Ameliorates Interstitial Lung Disease in SKG Mice
Abstract Number: 50

Intra-Articularly Delivering Lentivirus-Based CRISPR Interference Targeting Long Non-Coding RNA H19 in Synovial Fibroblasts Ameliorates Experimental Arthritis
Abstract Number: 51

Genetic Ablation of Inducible Nitric Oxide Synthase in TNF Transgenic Mice with Inflammatory-Erosive Arthritis Prevents Lymph Node Expansion and Decreases Synovial Infiltrates
Abstract Number: 52

Interferon-Alpha Protects Against Pain and Joint Damages in Experimental Arthritis and Is Associated with Expansion of Highly Suppressive Regulatory T Lymphocytes in Protected Mice and in Tocilizumab-Treated Rheumatoid Arthritis Patients
Abstract Number: 53

Cyclin-Dependent Kinase 4/6 Inhibitor: A Promising Development Candidate Targeting Synovial Hypertrophy for Rheumatoid Arthritis Treatment
Abstract Number: 54

In a Macaque Model of RA By Immunization with Citrullinated Peptides, the Valine in the 11 Position of the DRB1 Molecule Has Greater Impacts on T-Cell Response to Citrullinated Peptides Than the 70-74 Position in the Shared Epitope
Abstract Number: 55

Adipose Derived Stem Cell Suppressed Synovial Inflammation and Repaired Cartilage Destruction in Rheumatoid Arthritis Model Mice
Abstract Number: 56

Comparison of Metabolic Changes in Osteoarthritis and Rheumatoid Arthritis Mouse Models
Abstract Number: 57

Repository Corticotropin Injection (H.P. Acthar® Gel) Inhibits Bone Degradation in Rat Adjuvant-Induced Arthritis Model

« Previous Page
1
…
4
5
6
7
8
…
202
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].